Study details
Enrolling now
Ensuring Access to Optimal Therapy in CF: The ENACT Study
Arkansas Children's Hospital Research Institute
NCT IDNCT07148739ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
95
Study length
about 5.6 years
Ages
3+
Locations
2 sites in AR, WA
What this study is about
This trial is testing a treatment for Cystic Fibrosis (CF) that includes new drugs and genetic testing. The goal is to find out how these drugs work, who will respond well, and avoid unnecessary side effects or expensive treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Elexacaftor / Ivacaftor / Tezacaftor
- 2.Use therapeutic drug monitoring
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
Respiratory System Agent (Cytochrome P450 1A2 Inhibitors), ivacaftor
Drug routes
oral (Oral Tablet)
Body systems
Respiratory